Search Result

Pathways Recommended:	GPCR/G Protein

Results for "

Gαi

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (3) Apelin Receptor (APJ) (3) Arrestin (2) Bacterial (1) CXCR (2) Endogenous Metabolite (2) Isotope-Labeled Compounds (1) Reactive Oxygen Species (ROS) (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (5) Endocrinology (2) Infection (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-102076

0990CL	Adrenergic Receptor	Others
0990CL is a specific heterotrimeric Gαi subunit inhibitor by direct interaction with Gαi. 0990CL is able to block α2AR mediated regulation of cAMP .

HY-P0172A

ATI-2341 TFA 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P0172

ATI-2341 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P2106

Elabela(19-32) 5 Publications Verification	Arrestin Apelin Receptor (APJ)	Cardiovascular Disease
Elabela(19-32) is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) activates the Gαi1 and β-arrestin-2 signaling pathways with EC₅₀s of 8.6 nM and 166 nM. Elabela(19-32) induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .

HY-P2106A

Elabela(19-32) TFA 5 Publications Verification	Apelin Receptor (APJ) Arrestin	Cardiovascular Disease
Elabela(19-32) TFA is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) TFA activates the Gαi1 and β-arrestin-2 signaling pathways with EC₅₀s of 8.6 nM and 166 nM. Elabela(19-32) TFA induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .

HY-176780

Gαi2-IN-1	Others	Cancer
Gαi2-IN-1 (Compound 14) is a Gαi2 inhibitor. Gαi2-IN-1 significantly inhibits cancer cells migration induced by the chemotherapeutic drug, such as Vorinostat (HY-10221) and Docetaxel (HY-B0011). Gαi2-IN-1 can be used for cancers like prostate, breast and ovarian cancer research .

HY-171978

LM-189	Adrenergic Receptor	Cardiovascular Disease
LM-189, a G protein alpha subunit I (Gαi)-biased agonist, is a Gαi-biased ligand of β2-adrenergic receptor (β2AR). LM-189 stabilizes a distinct conformation in TM6 and increases the dynamics of ICL2. LM-189 can be used to develop the Gαi-biased β2AR agonists .

HY-171978A

LM-189 free base	Adrenergic Receptor	Cardiovascular Disease
LM-189 free base, a G protein alpha subunit I (Gαi)-biased agonist, is a Gαi-biased ligand of β2-adrenergic receptor (β2AR). LM-189 free base stabilizes a distinct conformation in TM6 and increases the dynamics of ICL2. LM-189 free base can be used to develop the Gαi-biased β2AR agonists .

HY-P11140

KSL-W	Bacterial Reactive Oxygen Species (ROS)	Infection Inflammation/Immunology
KSL-W is a multifunctional antibacterial peptide with immune regulatory function. KSL-W has a chemotactic effect on neutrophils. KSL-W can induce neutrophil F-actin polymerization dependent on the Gαi protein signaling pathway. KSL-W can inhibit the production of reactive oxygen species (ROS) in neutrophils. KSL-W can be used for research on infection control and inflammation regulation .

HY-P3346

NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal)	Apelin Receptor (APJ)	Cardiovascular Disease
NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) (compound 39) is a potent APJ agonist, with a K_i of 0.6 nM. NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) can activate Gαi1 (EC₅₀=0.8 nM) and recruit β-arrestin2 (EC₅₀=31 nM). NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) exhibits prolonged cardiac effects .

HY-153830

LacCer (d18:1/16:0) C16 Lactosylceramide (d18:1/16:0)	Endogenous Metabolite	Neurological Disease Metabolic Disease
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-153830S

LacCer (d18:1/16:0)-d3 C16 Lactosylceramide (d18:1/16:0)-d₃	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
LacCer (d18:1/16:0)-d₃ (C16 Lactosylceramide (d18:1/16:0)-d₃) is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

Cat. No.	Product Name	Target	Research Area

HY-P0172A

ATI-2341 TFA 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P0172

ATI-2341 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P2106

Elabela(19-32) 5 Publications Verification	Arrestin Apelin Receptor (APJ)	Cardiovascular Disease
Elabela(19-32) is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) activates the Gαi1 and β-arrestin-2 signaling pathways with EC₅₀s of 8.6 nM and 166 nM. Elabela(19-32) induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .

HY-P2106A

Elabela(19-32) TFA 5 Publications Verification	Apelin Receptor (APJ) Arrestin	Cardiovascular Disease
Elabela(19-32) TFA is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) TFA activates the Gαi1 and β-arrestin-2 signaling pathways with EC₅₀s of 8.6 nM and 166 nM. Elabela(19-32) TFA induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart .

HY-P4130

*MPS-Gαi2*	Peptides	Cancer
MPS-Gαi2 is a peptide (membrane-permeable sequence). MPS-Gαi2 can be used for the research of cell adhesion .

HY-P4131

*MPS-Gαi3*	Peptides	Others
MPS-Gαi3 is a cell penetrating peptide that can be used for drug delivery .

HY-P11140

KSL-W	Bacterial Reactive Oxygen Species (ROS)	Infection Inflammation/Immunology
KSL-W is a multifunctional antibacterial peptide with immune regulatory function. KSL-W has a chemotactic effect on neutrophils. KSL-W can induce neutrophil F-actin polymerization dependent on the Gαi protein signaling pathway. KSL-W can inhibit the production of reactive oxygen species (ROS) in neutrophils. KSL-W can be used for research on infection control and inflammation regulation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-153830

LacCer (d18:1/16:0) C16 Lactosylceramide (d18:1/16:0)	Microorganisms Source classification Saccharides Monosaccharides	Endogenous Metabolite
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

Cat. No.	Product Name	Chemical Structure

HY-153830S

LacCer (d18:1/16:0)-d3
LacCer (d18:1/16:0)-d₃ (C16 Lactosylceramide (d18:1/16:0)-d₃) is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

LacCer (d18:1/16:0)-d3

LacCer (d18:1/16:0)-d₃ (C16 Lactosylceramide (d18:1/16:0)-d₃) is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks